Phillips Andrew John — SEC Form 4 filings
SEC reporting owner CIK 1921956. 10 Form 4 filings on record with FilingPulse; latest filed 2026-08-11.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-02-15 to 2026-08-11. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| OnKure Therapeutics, Inc. (OKUR) | Director | 4 | — | — | 4 |
| Enliven Therapeutics, Inc. (ELVN) | Director | 3 | — | — | 3 |
| MoonLake Immunotherapeutics (MLTX) | Director | 3 | — | — | 3 |
Form 4 filings — Phillips Andrew John
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-11 | 4 | OnKure Therapeutics, Inc. (OKUR) | Grant/award (A): 22,350 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | MoonLake Immunotherapeutics (MLTX) | Grant/award (A): 22,195 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | OnKure Therapeutics, Inc. (OKUR) | Grant/award (A): 7,650 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | MoonLake Immunotherapeutics (MLTX) | Grant/award (A): 6,682 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | OnKure Therapeutics, Inc. (OKUR) | Grant/award (A): 7,650 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 20,491 (derivative) @ $0 | EDGAR |
| 2024-10-08 | 4 | OnKure Therapeutics, Inc. (OKUR) | Grant/award (A): 15,300 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | MoonLake Immunotherapeutics (MLTX) | Grant/award (A): 7,688 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4/A | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 23,364 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 16,835 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1921956 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →